NCT04421820 - BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

June 1, 2026

Study Completion Date

September 1, 2026

Conditions

Colorectal CancerPancreatic CancerGastric CancersCholangiocarcinoma

Interventions

DRUG

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)

625 mg/m2 IV over 30 minutes, q2weeks

DRUG

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)

320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks

Trial Locations (14)

33612

COMPLETED

Moffitt Cancer Center, Tampa

90095

COMPLETED

University of California, Los Angeles, Santa Monica

Unknown

RECRUITING

Cross Cancer Institue, Edmonton

RECRUITING

Juravinski Cancer Centre, Hamilton

RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa

RECRUITING

Princess Margaret Cancer Centre, Toronto

RECRUITING

Jewish General Hospital, Montreal

RECRUITING

McGill University Health Centre Glen Site, Montreal

RECRUITING

St. James Hospital, Dublin

RECRUITING

National Cancer Center, Goyang

RECRUITING

Kangbuk Samsung Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital - Yonsei University, Seoul